Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?
作者信息
Giordano A, Lin N U, Tolaney S M, Mayer E L
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
出版信息
Ann Oncol. 2024 Jan;35(1):10-14. doi: 10.1016/j.annonc.2023.11.003. Epub 2023 Nov 11.
PMID:37952893
Abstract
摘要
Zotero 插件